Technology-Enhanced Continuous Nursing System (TECNS) for Post-CABG Recovery
Efficacy of a Technology-Enhanced Continuous Nursing Intervention on Clinical Outcomes and Quality of Life Following Coronary Artery Bypass Grafting: A Randomized Controlled Trial
1 other identifier
interventional
358
1 country
1
Brief Summary
This is a prospective, randomized controlled trial to evaluate the effectiveness of a Technology-Enhanced Continuous Nursing System (TECNS) compared to routine care for patients after coronary artery bypass grafting (CABG). The study aims to determine if the TECNS intervention, which includes digital health tools, personalized tele-rehabilitation, and continuous nursing support, can improve clinical outcomes such as postoperative hemoglobin recovery, reduce long-term major adverse cardiac events (MACE), and enhance patients' quality of life and psychological well-being.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable coronary-artery-disease
Started Jan 2018
Longer than P75 for not_applicable coronary-artery-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedFirst Submitted
Initial submission to the registry
July 30, 2025
CompletedFirst Posted
Study publicly available on registry
August 12, 2025
CompletedAugust 12, 2025
July 1, 2025
7.5 years
July 30, 2025
August 4, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Change in Hemoglobin (Hb) Level
Change in blood hemoglobin concentration from baseline to 7 days after surgery, measured by laboratory analysis. This assesses the rate of postoperative hematopoietic recovery.
Baseline, Day 7
Major Adverse Cardiac Events (MACE)-Free Survival
The rate of survival free from MACE, defined as a composite of cardiovascular death, non-fatal myocardial infarction, stroke, or unplanned revascularization.
Up to 24 months
Secondary Outcomes (8)
Change in Red Blood Cell Indices
Baseline, Day 7
Change in Quality of Life (QoL)
Baseline, 1 month, 3 months, 6 months
Patient Satisfaction
1 month
Change in Interleukin-2 (IL-2) Level
Baseline, Day 7
Change in Interleukin-6 (IL-6) Level
Baseline, Day 7
- +3 more secondary outcomes
Study Arms (2)
Experimental: Technology-Enhanced Continuous Nursing System (TECNS) Group
EXPERIMENTALPatients received a comprehensive, 6-month continuous nursing program post-discharge. This included training on a dedicated smartphone app for educational modules; access to a moderated WeChat group for peer support and health tips; scheduled tele-rehabilitation calls from cardiac nurses for monitoring, education, and personalized guidance; and coordination with community health centers for follow-up. This was in addition to standard in-hospital care.
Active Comparator: Routine Care Group
ACTIVE COMPARATORPatients received standard institutional postoperative care, including basic discharge education (oral and written summaries on medication, diet, and activity). Post-discharge care consisted of scheduled outpatient follow-up visits at 1 and 3 months post-surgery, without the technology-enhanced continuous support components.
Interventions
A multi-faceted behavioral and educational intervention lasting 6 months post-discharge. It utilized a smartphone app, WeChat, tele-monitoring (phone/video calls), and community health partnerships to provide structured education, personalized rehabilitation plans, and continuous professional nursing support.
Standard institutional care including standard discharge instructions and routine outpatient follow-up appointments.
Eligibility Criteria
You may qualify if:
- Age between 18 and 75 years
- Meeting diagnostic criteria for elective CABG
- Able to provide informed consent
- Owned a smartphone and was willing to use it for the study intervention
You may not qualify if:
- Emergency or salvage CABG
- Severe coexisting conditions that could confound outcomes (e.g., end-stage renal disease, severe COPD \[GOLD stage IV\], active malignancy)
- Left ventricular ejection fraction \< 30%
- Participation in other clinical trials
- Severe cognitive impairment or psychiatric disorders precluding informed consent or adherence to the protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
July 30, 2025
First Posted
August 12, 2025
Study Start
January 1, 2018
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
August 12, 2025
Record last verified: 2025-07